TFG CMD CEO Presentation August 7, 2025 1 Building from a position of strength Mindful of headwinds We're not starting from zero Despite challenges, we're ahead Our strategy is working Our international businesses add strength The team will show you more Much of the heavy lifting is done We'll show you how – with data and realism With diversification, innovation and reach With numbers, plans and proof Today we're going to take it further With the launch of 5 extensions to BOLTS TFG CMD August 2025 2 Althoug ...

Second Quarter 2025 Earnings Report Speakers: DAVE GILBOA | Co-Founder & Co-CEO NEIL BLUMENTHAL | Co-Founder & Co-CEO STEVE MILLER | SVP & Chief Financial Officer Speakers: DAVE GILBOA | Co-Founder & Co-CEO NEIL BLUMENTHAL | Co-Founder & Co-CEO STEVE MILLER | SVP & Chief Financial Officer Forward-Looking Statements / Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities ...

Financial Performance & Capital Allocation - The company reported Adjusted EBITDAX of $749 million in 2Q25[30] - Adjusted Free Cash Flow (FCF) was $123 million in 2Q25[30] - A $750 million buyback authorization was reinstated, with a $250 million Accelerated Share Repurchase (ASR) planned for 2025[13] - The company is targeting $4.5 billion net debt around YE25[15] Operational Efficiency & Cost Reduction - A cost optimization and capital efficiency initiative is on track, projecting $40 million savings impact in 2025 and a $100 million run-rate in 2026[11] - Well costs have been reduced in all basins: Delaware (-7%), Midland (-5%), and DJ (-3%) since the beginning of 2025[30] Asset Divestment & Portfolio Optimization - Non-core DJ Basin asset sales of $435 million have been completed, exceeding the year-to-date divestment goal at an EBITDAX multiple >4x[12] - Divestments are expected to streamline DJ Basin operations, focusing on core near-term development areas[19] - 2026 production from divested assets is estimated at 10 thousand barrels of oil equivalent per day (MBoe/d), with a 4Q25 impact of approximately 12 MBoe/d[19] Production & Guidance - Oil production grew by 6% to 149 thousand barrels per day (MBbl/d) in 2Q25[30] - Total volumes are expected to increase by 5.5% from 2Q25 to 3Q25E[62]

Q2 2025 Results Talen Energy Corporation | August 7, 2025 Disclaimers The information contained herein, as well as any information that has been supplied orally in connection herewith, speaks only as of the date of this presentation. Talen Energy Corporation ("Talen," "TEC," the "Company," "we," "our," or "us") and our affiliates and representatives expressly disclaim any obligation to update any information contained herein, whether as a result of new information or circumstances, future events or otherwis ...

Second Quarter 2025 Highlights Non-GAAP Financial Measures In addition to our results determined in accordance with GAAP, we supplement our results with non-GAAP financial measures, including Adjusted Net Sales, Adjusted Gross Profit, Adjusted Gross Profit as a percentage of Adjusted Net Sales, Adjusted Selling, General and Administrative ("SG&A") Expenses, Adjusted SG&A as a percentage of Adjusted Net Sales, Adjusted Operating Income, Adjusted Operating Income as a percentage of Adjusted Net Sales, Adjuste ...

Non-GAAP Financial Measures This presentation includes certain financial measures that are not presented in accordance with generally accepted accounting principles in the United States ("GAAP), such as, among other things, Non-GAAP Gross Profit, Non-GAAP EPS, Free Cash Flow, Non-GAAP Gross Margin, Non-GAAP Operating Margin, Net Cash (Debt), Non-GAAP Operating Income (Loss), EBITDA, Non-GAAP Net Income (Loss), Non-GAAP Operating Expense, Gross Debt, and Adjusted EBITDA. Extreme Networks, Inc. (the "Company" ...

Financial Performance & Guidance - Worldwide ARIKAYCE revenue reached $107.4 million, an increase of 18.9%[43] - U.S. ARIKAYCE revenue was $68.7 million, up 7.7%[43] - Japan ARIKAYCE revenue was $30.7 million, a significant increase of 45.3%[43] - Europe & Rest of World ARIKAYCE revenue grew by 48.3% to $8.1 million[43] - The company is on track to achieve its 2025 ARIKAYCE revenue guidance of $405 to $425 million[44] - The company holds a strong capital position with approximately $1.9 billion in cash, cash equivalents, and marketable securities as of June 30, 2025[46] Clinical Development & Pipeline - All three late-stage assets (ARIKAYCE, brensocatib, and TPIP) have demonstrated clinical success[15] - Brensocatib is expected to launch in the U.S. in Q3 2025 for NCFB, pending regulatory approval[16] - Phase 2 BiRCh data for brensocatib in CRSsNP is expected by the end of 2025[16] - A futility analysis for the Phase 2 CEDAR trial of brensocatib in HS is anticipated in Q1 2026[16] - The Phase 2b study of TPIP in PAH exceeded expectations, showing a 35% reduction in PVR and a 35.5m improvement in 6MWD[39] - Phase 3 trial in PH-ILD is expected to initiate in 2H:25 and Phase 3 trial in PAH is expected to initiate in early 2026[16]

Financial Performance - The company's APE sales increased by 15% from C$19 billion to C$22 billion[17, 52] - New business CSM grew significantly by 37% from C$628 million to C$882 million[17, 52] - New business value increased by 20% from C$691 million to C$846 million[17, 52] - Core EPS increased by 2% from C$091 to C$095, while EPS increased significantly by 88%[19, 28] - Adjusted book value per share increased by 7%[20, 43] Business Segment Performance - Asia's APE sales increased by 31% from US$920 million to US$1233 billion[31] - Asia's new business value increased by 28% from US$346 million to US$451 million[31] - Asia's new business CSM increased by 34% from US$349 million to US$480 million[31] - Global WAM net flows increased by C$08 billion from C$01 billion to C$09 billion[17, 25]

Financial Performance & Profitability - Total revenues for 2Q'25 reached $110.0 million, a 9% increase year-over-year[56] - Adjusted loss from operations improved by 37% year-over-year, from $(54.485) million in 2Q'24 to $(34.187) million in 2Q'25[10, 86] - The company is on track to achieve profitability in 4Q'25, referring to adjusted income from operations[10, 18] - Cash position remains strong at $832.3 million as of June 30, 2025[10] Key Products & Pipeline Updates - VYVGART/VYVGART Hytrulo sales grew 14% year-over-year, reaching $26.5 million in 2Q'25, driven by increased market penetration and extension of DoT[56, 59] - ZL-1310 (DLL3 ADC) showed a 67% ORR in 2L SCLC across all doses and 79% ORR with 1.6 mg/kg (n=14)[42] - Bemarituzumab met the primary endpoint of overall survival in the global Ph3 FORTITUDE-101 study[10, 32] - KarXT's China NDA was accepted in January 2025, showing early and sustained reduction of positive and negative symptoms[26] Strategic Focus & Future Outlook - The company aims to unlock the blockbuster potential of VYVGART and VYVGART Hytrulo through execution excellence, targeting increased HCP coverage and supplemental insurance coverage[19, 20] - Multiple revenue inflections are expected through 2030, with an expected $2 billion revenue in 2028[18] - Zai Lab plans to initiate a global pivotal study of ZL-1310 in 2L ES-SCLC in 2H'25[15, 40]

CACI International Inc Q4 FY25 Earnings Conference Call August 7, 2025 EXPERTISE and TECHNOLOGY 1 | CACI Proprietary Information EXPERTISE and TECHNOLOGY for National Security for National Security Forward-looking statements 2 | CACI Proprietary Information On today's call John Mengucci President and Chief Executive Officer Jeff MacLauchlan Chief Financial Officer and Treasurer 3 | CACI Proprietary Information Honoring the Legacy of Mike Daniels There are statements made herein that do not address historica ...